Itraconazole in onychomycosis. Open and double-blind studies

Fifteen patients with onychomycosis caused by Trichophyton rubrum or T. mentagrophytes were treated with 50 mg itraconazole daily for 3 to 6 months. Fingernail infections were cured in two patients and two responded with marked improvement, e.g. small residual lesion remained and positive microscopy...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Acta dermato-venereologica 1990-01, Vol.70 (2), p.137-140
Hauptverfasser: Walsøe, I, Stangerup, M, Svejgaard, E
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 140
container_issue 2
container_start_page 137
container_title Acta dermato-venereologica
container_volume 70
creator Walsøe, I
Stangerup, M
Svejgaard, E
description Fifteen patients with onychomycosis caused by Trichophyton rubrum or T. mentagrophytes were treated with 50 mg itraconazole daily for 3 to 6 months. Fingernail infections were cured in two patients and two responded with marked improvement, e.g. small residual lesion remained and positive microscopy. The infected toenails were markedly improved in nine of 13 patients. Twenty-seven patients with T. rubrum infected nails were given 100 mg itraconazole daily for 6 to 8 months. Fingernails were cured in nine of eleven patients, while toenail infections were cured in one and markedly improved in 14 of 25 cases. Responses to 100 mg itraconazole versus 500 mg griseofulvin daily for 6 months were compared and evaluated in 20 patients with onychomycosis caused by T. rubrum or T. mentagrophytes. Fingernail infections responded equally well to both drugs with half of the cases cured or markedly improved, whereas toenails responded better to itraconazole, e.g. 4 of 9 were markedly improved versus one of 10 on griseofulvin. In patients given 50 mg itraconazole daily a significantly better response was observed in persons below 30 years of age compared to older individuals. Also, side-effects which were mainly mild and located to the gastro-intestinal tract or the central nervous system were seen less often in this group of patients on the low dose. Follow-up studies showed that cured nails remained cured, that markedly improved toenails continued to improve until cure in three of 21 patients but that aggravation took place through the one year of follow-up in more than half of the patients evaluated as markedly improved at the end of treatment.
doi_str_mv 10.2340/0001555570137140
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79677271</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79677271</sourcerecordid><originalsourceid>FETCH-LOGICAL-c402t-199f41d114669bddde395c8b746eafd3a2e0741f5cb158341cd2fc5724193a2a3</originalsourceid><addsrcrecordid>eNpdkL1LxEAUxBdRznja2wip7HLu249sFmzk8OPg4Bqtw2b3BSNJNmaTIv71JtyB4Gsew29miiHkFuiGcUEfKKUg51MUuAJBz0gEqYSEUanOSbTgZOGX5CqEr1kyCdmKrECnGnQWkcfd0BvrW_Pja4yrNvbtZD99M1kfqrCJDx22sWld7PxY1JgUdTWLMIyuwnBNLkpTB7w5_TX5eHl-374l-8Prbvu0T6ygbEhA61KAAxBpqgvnHHItbVYokaIpHTcMqRJQSluAzLgA61hppWIC9AwNX5P7Y2_X--8Rw5A3VbBY16ZFP4Zc6VQppmA20qPR9j6EHsu866vG9FMONF8Gy_8PNkfuTt1j0aD7CxwX4r_l9GSu</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79677271</pqid></control><display><type>article</type><title>Itraconazole in onychomycosis. Open and double-blind studies</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Walsøe, I ; Stangerup, M ; Svejgaard, E</creator><creatorcontrib>Walsøe, I ; Stangerup, M ; Svejgaard, E</creatorcontrib><description>Fifteen patients with onychomycosis caused by Trichophyton rubrum or T. mentagrophytes were treated with 50 mg itraconazole daily for 3 to 6 months. Fingernail infections were cured in two patients and two responded with marked improvement, e.g. small residual lesion remained and positive microscopy. The infected toenails were markedly improved in nine of 13 patients. Twenty-seven patients with T. rubrum infected nails were given 100 mg itraconazole daily for 6 to 8 months. Fingernails were cured in nine of eleven patients, while toenail infections were cured in one and markedly improved in 14 of 25 cases. Responses to 100 mg itraconazole versus 500 mg griseofulvin daily for 6 months were compared and evaluated in 20 patients with onychomycosis caused by T. rubrum or T. mentagrophytes. Fingernail infections responded equally well to both drugs with half of the cases cured or markedly improved, whereas toenails responded better to itraconazole, e.g. 4 of 9 were markedly improved versus one of 10 on griseofulvin. In patients given 50 mg itraconazole daily a significantly better response was observed in persons below 30 years of age compared to older individuals. Also, side-effects which were mainly mild and located to the gastro-intestinal tract or the central nervous system were seen less often in this group of patients on the low dose. Follow-up studies showed that cured nails remained cured, that markedly improved toenails continued to improve until cure in three of 21 patients but that aggravation took place through the one year of follow-up in more than half of the patients evaluated as markedly improved at the end of treatment.</description><identifier>ISSN: 0001-5555</identifier><identifier>EISSN: 1651-2057</identifier><identifier>DOI: 10.2340/0001555570137140</identifier><identifier>PMID: 1969198</identifier><language>eng</language><publisher>Sweden</publisher><subject>Adolescent ; Adult ; Aged ; Antifungal Agents - administration &amp; dosage ; Antifungal Agents - therapeutic use ; Child ; Double-Blind Method ; Female ; Follow-Up Studies ; Humans ; Itraconazole ; Ketoconazole - administration &amp; dosage ; Ketoconazole - analogs &amp; derivatives ; Ketoconazole - therapeutic use ; Male ; Middle Aged ; Onychomycosis - drug therapy ; Onychomycosis - microbiology ; Random Allocation ; Recurrence</subject><ispartof>Acta dermato-venereologica, 1990-01, Vol.70 (2), p.137-140</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c402t-199f41d114669bddde395c8b746eafd3a2e0741f5cb158341cd2fc5724193a2a3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1969198$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Walsøe, I</creatorcontrib><creatorcontrib>Stangerup, M</creatorcontrib><creatorcontrib>Svejgaard, E</creatorcontrib><title>Itraconazole in onychomycosis. Open and double-blind studies</title><title>Acta dermato-venereologica</title><addtitle>Acta Derm Venereol</addtitle><description>Fifteen patients with onychomycosis caused by Trichophyton rubrum or T. mentagrophytes were treated with 50 mg itraconazole daily for 3 to 6 months. Fingernail infections were cured in two patients and two responded with marked improvement, e.g. small residual lesion remained and positive microscopy. The infected toenails were markedly improved in nine of 13 patients. Twenty-seven patients with T. rubrum infected nails were given 100 mg itraconazole daily for 6 to 8 months. Fingernails were cured in nine of eleven patients, while toenail infections were cured in one and markedly improved in 14 of 25 cases. Responses to 100 mg itraconazole versus 500 mg griseofulvin daily for 6 months were compared and evaluated in 20 patients with onychomycosis caused by T. rubrum or T. mentagrophytes. Fingernail infections responded equally well to both drugs with half of the cases cured or markedly improved, whereas toenails responded better to itraconazole, e.g. 4 of 9 were markedly improved versus one of 10 on griseofulvin. In patients given 50 mg itraconazole daily a significantly better response was observed in persons below 30 years of age compared to older individuals. Also, side-effects which were mainly mild and located to the gastro-intestinal tract or the central nervous system were seen less often in this group of patients on the low dose. Follow-up studies showed that cured nails remained cured, that markedly improved toenails continued to improve until cure in three of 21 patients but that aggravation took place through the one year of follow-up in more than half of the patients evaluated as markedly improved at the end of treatment.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Antifungal Agents - administration &amp; dosage</subject><subject>Antifungal Agents - therapeutic use</subject><subject>Child</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Itraconazole</subject><subject>Ketoconazole - administration &amp; dosage</subject><subject>Ketoconazole - analogs &amp; derivatives</subject><subject>Ketoconazole - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Onychomycosis - drug therapy</subject><subject>Onychomycosis - microbiology</subject><subject>Random Allocation</subject><subject>Recurrence</subject><issn>0001-5555</issn><issn>1651-2057</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1990</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkL1LxEAUxBdRznja2wip7HLu249sFmzk8OPg4Bqtw2b3BSNJNmaTIv71JtyB4Gsew29miiHkFuiGcUEfKKUg51MUuAJBz0gEqYSEUanOSbTgZOGX5CqEr1kyCdmKrECnGnQWkcfd0BvrW_Pja4yrNvbtZD99M1kfqrCJDx22sWld7PxY1JgUdTWLMIyuwnBNLkpTB7w5_TX5eHl-374l-8Prbvu0T6ygbEhA61KAAxBpqgvnHHItbVYokaIpHTcMqRJQSluAzLgA61hppWIC9AwNX5P7Y2_X--8Rw5A3VbBY16ZFP4Zc6VQppmA20qPR9j6EHsu866vG9FMONF8Gy_8PNkfuTt1j0aD7CxwX4r_l9GSu</recordid><startdate>19900101</startdate><enddate>19900101</enddate><creator>Walsøe, I</creator><creator>Stangerup, M</creator><creator>Svejgaard, E</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19900101</creationdate><title>Itraconazole in onychomycosis. Open and double-blind studies</title><author>Walsøe, I ; Stangerup, M ; Svejgaard, E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c402t-199f41d114669bddde395c8b746eafd3a2e0741f5cb158341cd2fc5724193a2a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1990</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Antifungal Agents - administration &amp; dosage</topic><topic>Antifungal Agents - therapeutic use</topic><topic>Child</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Itraconazole</topic><topic>Ketoconazole - administration &amp; dosage</topic><topic>Ketoconazole - analogs &amp; derivatives</topic><topic>Ketoconazole - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Onychomycosis - drug therapy</topic><topic>Onychomycosis - microbiology</topic><topic>Random Allocation</topic><topic>Recurrence</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Walsøe, I</creatorcontrib><creatorcontrib>Stangerup, M</creatorcontrib><creatorcontrib>Svejgaard, E</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Acta dermato-venereologica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Walsøe, I</au><au>Stangerup, M</au><au>Svejgaard, E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Itraconazole in onychomycosis. Open and double-blind studies</atitle><jtitle>Acta dermato-venereologica</jtitle><addtitle>Acta Derm Venereol</addtitle><date>1990-01-01</date><risdate>1990</risdate><volume>70</volume><issue>2</issue><spage>137</spage><epage>140</epage><pages>137-140</pages><issn>0001-5555</issn><eissn>1651-2057</eissn><abstract>Fifteen patients with onychomycosis caused by Trichophyton rubrum or T. mentagrophytes were treated with 50 mg itraconazole daily for 3 to 6 months. Fingernail infections were cured in two patients and two responded with marked improvement, e.g. small residual lesion remained and positive microscopy. The infected toenails were markedly improved in nine of 13 patients. Twenty-seven patients with T. rubrum infected nails were given 100 mg itraconazole daily for 6 to 8 months. Fingernails were cured in nine of eleven patients, while toenail infections were cured in one and markedly improved in 14 of 25 cases. Responses to 100 mg itraconazole versus 500 mg griseofulvin daily for 6 months were compared and evaluated in 20 patients with onychomycosis caused by T. rubrum or T. mentagrophytes. Fingernail infections responded equally well to both drugs with half of the cases cured or markedly improved, whereas toenails responded better to itraconazole, e.g. 4 of 9 were markedly improved versus one of 10 on griseofulvin. In patients given 50 mg itraconazole daily a significantly better response was observed in persons below 30 years of age compared to older individuals. Also, side-effects which were mainly mild and located to the gastro-intestinal tract or the central nervous system were seen less often in this group of patients on the low dose. Follow-up studies showed that cured nails remained cured, that markedly improved toenails continued to improve until cure in three of 21 patients but that aggravation took place through the one year of follow-up in more than half of the patients evaluated as markedly improved at the end of treatment.</abstract><cop>Sweden</cop><pmid>1969198</pmid><doi>10.2340/0001555570137140</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0001-5555
ispartof Acta dermato-venereologica, 1990-01, Vol.70 (2), p.137-140
issn 0001-5555
1651-2057
language eng
recordid cdi_proquest_miscellaneous_79677271
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Adolescent
Adult
Aged
Antifungal Agents - administration & dosage
Antifungal Agents - therapeutic use
Child
Double-Blind Method
Female
Follow-Up Studies
Humans
Itraconazole
Ketoconazole - administration & dosage
Ketoconazole - analogs & derivatives
Ketoconazole - therapeutic use
Male
Middle Aged
Onychomycosis - drug therapy
Onychomycosis - microbiology
Random Allocation
Recurrence
title Itraconazole in onychomycosis. Open and double-blind studies
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T08%3A10%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Itraconazole%20in%20onychomycosis.%20Open%20and%20double-blind%20studies&rft.jtitle=Acta%20dermato-venereologica&rft.au=Wals%C3%B8e,%20I&rft.date=1990-01-01&rft.volume=70&rft.issue=2&rft.spage=137&rft.epage=140&rft.pages=137-140&rft.issn=0001-5555&rft.eissn=1651-2057&rft_id=info:doi/10.2340/0001555570137140&rft_dat=%3Cproquest_cross%3E79677271%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79677271&rft_id=info:pmid/1969198&rfr_iscdi=true